Group 1 - The core viewpoint of the article is that the International Medical Proton Therapy Center's Phase I project is progressing as planned and will commence operations upon obtaining the necessary administrative approvals [1] - The company will determine the specific investment progress of the Phase II project based on the actual amount raised from the current private placement [1]

Core Insights - The company has experienced significant growth in overall business scale since the full opening of Xi'an International Medical Center Hospital, with revenue increasing from 0.991 billion in 2019 to 4.82 billion in 2024 [2] - The outpatient volume is projected to reach 2.57 million visits per year in 2024, indicating a steady development trend and increasing brand influence and patient recognition [2] - The company is focusing on enhancing internal cost control, optimizing management processes, and improving operational efficiency [2] - As the company's operating performance gradually improves, it plans to further optimize its capital structure and reduce debt levels [2]

Group 1 - The hair medical concept sector declined by 0.70%, ranking among the top declines in concept sectors, with notable declines in companies such as International Medicine, Kanghui Co., and Langzi Co. [1] - Among the hair medical concept stocks, five companies saw price increases, with *ST Meigu rising by 2.68%, *ST Jinbi by 2.12%, and Baicheng Pharmaceutical by 1.31% [1][3] - The main capital outflow from the hair medical concept sector today was 336 million yuan, with 18 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net capital outflows were led by Kids Wang with a net outflow of 96.59 million yuan, followed by Aimeike with 65.02 million yuan, International Medicine with 31.64 million yuan, and Shuiyang Co. with 30.71 million yuan [2] - The stocks with the highest net capital inflows included Kanghui Co. with 3.44 million yuan, *ST Jinbi with 2.01 million yuan, and Xiaofang Pharmaceutical with 1.34 million yuan [2] - The hair medical concept sector had a notable trading volume, with Kids Wang showing a turnover rate of 9.49% and Aimeike at 1.43% [2][3]

西安国际医学投资股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示 1.本次股东会会议召开期间没有增加、否决或变更提案。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-058 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1.现场会议召开时间：2025年12月19日（星期五）下午2:30 网络投票时间为：2025年12月19日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025年12月19日的交易时间，即09:15一09:25，09:30一11:30和13:00一15:00；通过深圳证券交易所互联 网系统投票的具体时间为：2025年12月19日09:15一15:00期间任意时间。 2.现场会议召开地点：西安市高新区西太路737号西安国际医学中心医院北院区保障楼5层会议室 3.召开方式：本次股东会采取现场投票与网络投票相结合的方式 4.召集人：西安国际医学投资股份有限公司董事会 5.主持人：史今 ...

Core Viewpoint - International Medicine (000516.SZ) plans to raise up to 1.008 billion yuan through a private placement, focusing on three main areas: smart healthcare projects, proton therapy center phase II, and working capital supplementation [2][4] Group 1: Fundraising and Investment Focus - The fundraising will allocate 638 million yuan to smart healthcare projects, nearly 100 million yuan to the proton therapy center phase II, and 270 million yuan for working capital [2] - The smart healthcare project aims to utilize idle assets to "activate stock assets," responding to both policy demands and the need for asset revitalization [2][5] - The company intends to use 270 million yuan from the fundraising to meet operational funding needs and optimize its capital structure [2][5] Group 2: Financial Challenges - As of September 30, 2025, the company's debt-to-asset ratio reached 68.80%, significantly higher than the industry average, with a sharp decline in cash reserves from 1.52 billion yuan at the end of 2021 to 331 million yuan [4][7] - The company has substantial short-term borrowings of 995 million yuan and non-current liabilities due within a year totaling 905 million yuan, leading to a total of nearly 1.9 billion yuan in rigid debt due within a year [4] - The company has faced significant losses over the past four years, with cumulative losses reaching 2.621 billion yuan [7] Group 3: Market Opportunities and Strategic Adjustments - The company views the fundraising as a strategic adjustment to address market changes, financial pressures, and idle assets [3] - The smart healthcare project and proton therapy center phase II are seen as key initiatives to capitalize on the "silver economy" and high-end medical development opportunities [4][6] - The proton therapy center phase II aims to fill a market gap in the northwest region, where no proton therapy centers are currently operational [6] Group 4: Operational Efficiency and Cost Management - The company is attempting to improve operational efficiency through clinical pathway management and cost structure optimization [8][9] - As of the third quarter of 2025, the company reported a management expense ratio of 10.99%, a decrease from previous periods, indicating initial success in cost control [8] - The company plans to continue enhancing service quality and patient experience while exploring various specialized medical fields to build competitive advantages [9]

证券日报网讯 12月19日晚间，国际医学（000516）发布公告称，公司2025年第二次临时股东会审议通 过《关于公司符合向特定对象发行股票条件的议案》《关于公司向特定对象发行股票方案的议案》《关 于公司2025年度向特定对象发行股票预案的议案》等多项议案。 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-058 西安国际医学投资股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1.本次股东会会议召开期间没有增加、否决或变更提案。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1.现场会议召开时间：2025 年 12 月 19 日（星期五）下午 2:30 网络投票时间为：2025 年 12 月 19 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 12 月 19 日的交易时间，即 09:15—09:25，09:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网系统投票的具体时间为：2025 年 12 月 19 日 09:15—15:00 期间任意时间。 2.现场会议召开地点：西安市高新区西太路 737 号西安国际医学中心 医院北院区保障楼 5 层会议室 3.召开方式：本次股东会采取现场投票与网络投票相结合的方式 4.召集人：西安国际医学投资股份有限公司董事会 5. ...

北 京 市 康 达 （ 西 安 ） 律 师 事 务 所 BEIJING KANGDA (XI'AN) LAW FIRM 陕西省西安市太白南路 139 号荣禾·云图中心 7 层、15、24 层 7&15F, Ronghe Cloud Centre, No.139, South Taibai Road, Xi'an, Shaanxi Province, P.R.C 邮编/Zip Code:710065 电话/Tel:029-88360128 传真/Fax:029-88360129 北京市康达（西安）律师事务所 关于西安国际医学投资股份有限公司 2025 年第二次临时股东会的 法 律 意 见 书 致: 西安国际医学投资股份有限公司 北京市康达（西安）律师事务所接受西安国际医学投资股份有限公司（以下 简称"公司"）的委托，指派田慧律师、吕岩律师（以下简称"本所律师"）出 席公司 2025 年第二次临时股东会（以下简称"本次股东会"），并出具法律意 见书。 本所律师声明事项： 1.在本法律意见书中，本所律师仅就本次股东会的召集与召开程序、召集人 和出席会议人员的资格、会议的表决程序以及表决结果进行审查和见证后发表法 律 ...

Core Viewpoint - The company has confirmed that its non-public stock issuance aligns with its development strategy and has received necessary approvals from the board, shareholders, and regulatory authorities [2] Group 1 - The non-public stock issuance is intended to support the company's business development and enhance its operational capabilities [2] - The fundraising through non-public issuance is seen as beneficial for the long-term development of the company and the interests of all shareholders [2]

证券日报网讯 12月18日，国际医学在互动平台回答投资者提问时表示，大股东资信状况良好，具备较 强的资金偿还能力，不存在流动性风险，质押风险可控。 （文章来源：证券日报） ...